Media coverage about Grifols SA, Barcelona (NASDAQ:GRFS) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Grifols SA, Barcelona earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.9599684506404 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s analysis:
- ETFs with exposure to Grifols SA : December 19, 2017 (finance.yahoo.com)
- Reviewing Mateon Therapeutics (MATN) & Grifols SA, Barcelona (GRFS) (americanbankingnews.com)
- Grifols SA, Barcelona (GRFS) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- Comparing Anavex Life Sciences (AVXL) and Grifols SA, Barcelona (GRFS) (americanbankingnews.com)
Shares of Grifols SA, Barcelona (GRFS) traded up $0.23 during mid-day trading on Thursday, reaching $22.18. 283,080 shares of the company’s stock were exchanged, compared to its average volume of 619,167. The firm has a market capitalization of $5,740.00, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.66 and a beta of 1.02. The company has a current ratio of 3.17, a quick ratio of 1.39 and a debt-to-equity ratio of 1.69. Grifols SA, Barcelona has a 1 year low of $15.47 and a 1 year high of $24.20.
About Grifols SA, Barcelona
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.